Herpes Zoster
Conditions
Interventions
Exposure group:Routine treatment + Chonglou detoxifying tincture
Sponsors
Tianjin Research Institute of Traditional Chinese Medicine Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1: Meets the following diagnostic criteria: Meets the Western medical diagnostic criteria for Herpes Zoster or the relevant diagnostic criteria in the "Chinese Expert Consensus on Herpes Zoster 2022"; Meets the diagnostic criteria for "Liver Meridian Heat Syndrome" in the "TCM Guidelines for Snake Gall Bladder 2014"; 2: Participants aged between 18 and 70 years old; 3: The onset of pain or rash due to Herpes Zoster is within 7 days; 4: The pain is localized to the head, face, trunk, limbs, or neck; 5: The 10-point Visual Analog Scale (VAS) score must be completed before enrollment; 6: Participants have good compliance, normal cognitive function, and can tolerate the treatment in this study; 7: Participants have understood the trial content and voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1: Special types of herpes zoster: abortive herpes zoster, rash-free herpes zoster, herpes zoster involving the central nervous system, visceral herpes zoster, generalized herpes zoster, disseminated herpes zoster, etc. 2: Pregnant or breastfeeding women, or participants with plans to become pregnant (or whose partners have plans to become pregnant) during the trial period. 3: Participants with known allergies to the drugs or components used in this study. 4: Participants with severe local skin infections or other comorbidities that make treatment procedures unsuitable. 5: Participants with severe internal medical conditions, malignant tumors, or mental disorders. 6: Participants with intellectual disabilities or language barriers that prevent adequate informed consent or cooperation in treatment and assessment. 7: Participants who have used the following medications systemically or locally for more than 7 days prior to enrollment: antiviral drugs (e.g., acyclovir, valacyclovir, famciclovir, brivudine, sodium phosphonoformate), glucocorticoids (e.g., prednisone), immunomodulatory drugs (e.g., thymopentin, interferon), and traditional Chinese medicine formulations or injections with heat-clearing, detoxifying, stasis-resolving, and pain-relieving effects. 8: Participants who have received treatment for severe cardiovascular or pulmonary diseases within the past 3 months and whose conditions remain unstable, such as angina pectoris, congestive heart failure, bundle branch block, arrhythmias, or those with implanted cardiac pacemakers. 9: Participants with a history of impaired liver or kidney function. 10: Participants who have other causes of pain in the herpes zoster region, such as compressive neuropathy (spinal stenosis) or fibromyalgia, or who have pre-existing painful conditions in the local area that may affect the assessment of pain during this trial. 11: Participants with a history of alcohol abuse, drug abuse, or substance dependence. 12: Participants who have participated in or are currently participating in other clinical trials within the past month prior to screening. 13: Participants deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Herpes Evaluation Indicators;Pain Assessment Indicators;Incidence Rate Indicator of Postherpetic Neuralgia after Herpes Zoster;Overall Efficiency Evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep Quality Assessment Indicators;Anxiety State Rating Scale; | — |
Countries
China
Contacts
Public ContactLitao Zhang
Tianjin Research Institute of Traditional Chinese Medicine Affiliated Hospital
Outcome results
None listed